Moreover, while it has been clearly demonstrated that the inhibition of LRRK2 kinase activity is effective in pre-clinical models of familial and iPD, the relevant substrate(s) of LRRK2 linked to PD pathogenesis or progression have not been identified yet, highlighting the need for continued work in this area. This evidence concerns the gene LRRK2 and Parkinson disease.